Nonsedating anxiolytics.

Autor: Cerne R; Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA; RespireRx Pharmaceuticals Inc., Glen Rock, NJ, USA; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Electronic address: rok_cerne@yahoo.com., Smith JL; Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, Indianapolis, IN, USA., Chrzanowska A; Medical University of Warsaw, Warsaw, Poland., Lippa A; RespireRx Pharmaceuticals Inc., Glen Rock, NJ, USA.
Jazyk: angličtina
Zdroj: Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2024 Dec; Vol. 245, pp. 173895. Date of Electronic Publication: 2024 Oct 24.
DOI: 10.1016/j.pbb.2024.173895
Abstrakt: Anxiety disorders are the most prevalent psychiatric pathology with substantial cost to society, but the existing treatments are often inadequate. This has rekindled the interest in the GABA A -receptor (GABA A R) positive allosteric modulator (PAM) compounds, which have a long history in treatment of anxiety beginning with diazepam, chlordiazepoxide, and alprazolam. While the GABA A R PAMs possess remarkable anxiolytic efficacy, they have fallen out of favor due to a host of adverse effects including sedation, motor impairment, addictive potential and tolerance development. A substantial effort was thus devoted to the design of GABA A R PAMs as anxiolytics with reduced sedative liabilities. Several non-benzodiazepine (BZD) GABA A PAMs progressed to clinical trials (bretazenil, abecarnil, alpidem, and ocinaplon) with alpidem obtaining regulatory approval as anxiolytic, but later withdrawn from market due to hepatotoxicity. Advances in molecular biology gave birth to a host of subtype selective GABA A R-PAMs which suffered from signs of sedation and motor impairment and only three compounds progressed to proof-of-concept studies (TPA-023, AZD7325 and PF-06372865). TPA-023 was terminated due to toxicity in preclinical species while AZD7325 and PF-06372865 did not achieve efficacy endpoints in patients. We highlight a new compound, KRM-II-81, that is an imidazodiazepine selective for GABA A R containing α2/3 and β3 proteins. In preclinical studies KRM-II-81 produced anxiolytic-like effects but with minimal sedation, respiratory depression, and abuse liability. Thus, KRM-II-81 is a newly discovered, non- BZD anxiolytic compound, which targets a selective population of GABA A R for improved therapeutic gain and reduced side effects.
Competing Interests: Declaration of competing interest Authors report no conflict of interest with the exception that Rok Cerne and Arnold Lippa are associated with RespireRx Pharmaceuticals Inc. that has licensed KRM-II-81 for development.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: